S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.04%) $0.927
USD/NOK
(0.00%) $10.84
USD/GBP
(-0.11%) $0.791
USD/RUB
(-0.21%) $92.38

Realtime updates for Travere Therapeutics, [TVTX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
50.00%
return -0.99%
SELL
60.00%
return 1.13%
Last Updated28 Mar 2024 @ 16:00

0.52% $ 7.71

BUY 63066 min ago

@ $8.24

Issued: 14 Feb 2024 @ 15:41


Return: -6.38%


Previous signal: Feb 13 - 15:50


Previous signal: Sell


Return: 3.45 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases...

Stats
Today's Volume 698 158
Average Volume 1.24M
Market Cap 586.72M
EPS $0 ( 2024-02-15 )
Next earnings date ( $-0.950 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -1.520
ATR14 $0.00700 (0.09%)
Insider Trading
Date Person Action Amount type
2024-01-31 Dube Eric M Buy 135 000 Common Stock
2024-02-01 Dube Eric M Sell 9 106 Common Stock
2024-01-31 Dube Eric M Buy 360 000 Employee stock option (right to buy)
2024-02-01 Dube Eric M Sell 10 016 Common Stock
2024-01-31 Rote William E. Buy 25 000 Common Stock
INSIDER POWER
89.01
Last 100 transactions
Buy: 2 015 500 | Sell: 112 292

Volume Correlation

Long: -0.43 (neutral)
Short: -0.89 (strong negative)
Signal:(34.012) Neutral

Travere Therapeutics, Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Travere Therapeutics, Correlation - Currency/Commodity

The country flag 0.50
( neutral )
The country flag 0.52
( weak )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.32
( neutral )

Travere Therapeutics, Financials

Annual 2023
Revenue: $145.24M
Gross Profit: $88.86M (61.18 %)
EPS: $-1.500
Q4 2023
Revenue: $45.06M
Gross Profit: $28.64M (63.57 %)
EPS: $-1.180
Q3 2023
Revenue: $37.10M
Gross Profit: $35.81M (96.53 %)
EPS: $1.980
Q2 2023
Revenue: $59.70M
Gross Profit: $57.71M (96.67 %)
EPS: $-1.130

Financial Reports:

No articles found.

Travere Therapeutics,

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators